Medical Condition News

RSS

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

Pennsylvania Bio today issued a new report on cancer that details the research happening through Pennsylvania companies to develop new products to diagnose and treat cancer.

12 Sep 2010

New neurological deficit behind amblyopia

Researchers at New York University's Center for Neural Science have identified a new neurological deficit behind amblyopia, or "lazy eye." Their findings, which appear in the most recent issue of the Journal of Neuroscience, shed additional light on how amblyopia results from disrupted links between the brain and normal visual processing.

10 Sep 2010

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit™, in bladder cancer patients requiring bladder removal.

10 Sep 2010

Resverlogix announces key changes to Phase 2 ASSURE trial

Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.

10 Sep 2010

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, supports the U.S. Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF).

10 Sep 2010

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.

10 Sep 2010

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Varian Medical Systems is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

10 Sep 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Florida-based biopharmaceutical company Oragenics, Inc. has announced the continued retail expansion of its oral care probiotics EvoraPlus and EvoraKids™ with an initial order from Harris Teeter. It is anticipated that the products will be available at Harris Teeter stores in September 2010.

10 Sep 2010

Legal and moral reasons prevent most Oregon hospices from participation in 'Death with Dignity Act'

A survey in the latest issue of the Hastings Center Report found that most hospices in Oregon, the first state to legalize physician-assistance in dying, either do not participate in or have limited participation in requests for such assistance. Both legal and moral reasons are identified.

10 Sep 2010

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Ortho Biotech Oncology Research & Development, a unit of Cougar Biotechnology, Inc., today announced that it has unblinded the Phase 3 study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer (also referred to as castration-resistant prostate cancer) whose disease has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel.

10 Sep 2010

Current treatment strategies for mood and addictive disorders

Sober Living in Delray, Recovery Residences, in conjunction with the "Moment of Change - Intervention Approaches for Professionals - 32nd National Conference" is sponsoring the presentation of "Mood Disorders and Addictive Disorders: Current Treatment Strategies" at 7:00 PM on Wednesday, September 29th, 2010 at the Old Calypso Restaurant in Delray Beach, Florida.

10 Sep 2010

Nucletron to present innovative cancer treatment during ESTRO29

Nucletron, a leading provider of state of the art radiotherapy solutions for cancer treatment, today announced a large number of exciting innovations for precise cancer treatment that will be in the spotlight during ESTRO29 in Barcelona. The company will be showcasing the latest developments in cancer treatment solutions for both brachytherapy and external beam.

10 Sep 2010

Cancer Research UK launches world's first urban running lane on London's Southbank

Dawdling pedestrians test the patience of over a quarter of outdoor runners (27 per cent) according to a poll of 1,000 runners by Cancer Research UK, to launch its Run10k series. The results have been highlighted as the charity launches the world's first urban running lane on London's Southbank with the help of celebrity runner Nell McAndrew.

10 Sep 2010

Scottish government proposes minimum price to tackle alcohol misuse

The Scottish government has confirmed that it proposes to introduce a minimum price of 45p per unit of alcohol, in order to tackle alcohol misuse and prevent related illnesses.

10 Sep 2010

'Seeking mental health treatment' is not a criteria for revocation of security clearance

Yesterday, presumably in response to a series of articles in the September issue of the Foreign Service Journal, Secretary of State Clinton issued an internal statement urging employees needing mental health treatment to get it, stating quite clearly that no Foreign Service Officer had ever lost a security clearance due to having sought mental health treatment. Concerned Foreign Service Officers wants to set the record straight.

10 Sep 2010

Using opioids at end-of-life care proves effective to control pain

Patients who choose to spend their last days at home with specialized care and monitoring can safely be given opioids to control pain and other symptoms without reducing survival time, according to a study published in Journal of Palliative Medicine (JPM), a peer-reviewed journal from Mary Ann Liebert, Inc.

10 Sep 2010

FASD ONE releases three research papers on Fetal Alcohol Spectrum Disorder

To mark Fetal Alcohol Spectrum Disorder Awareness Day the 9th day of the 9th month, the FASD Ontario Network of Expertise (FASD ONE) is releasing three research papers focused on the pressing issues identified by Ontario families and service providers. The papers cover topics of respite care, education, and effective practices.

10 Sep 2010

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

Mexican-American stroke survivors with a heart rhythm disorder have more than twice the risk for another stroke compared to non-Hispanic whites, according to a study published in Stroke: Journal of the American Heart Association.

10 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

Medical Condition News

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Pennsylvania Bio issues new report on Pennsylvania's bioscience companies' efforts for cancer research

New neurological deficit behind amblyopia

Johns Hopkins added as second clinical trial site in Tengion Neo-Urinary Conduit Phase I clinical trial

Resverlogix announces key changes to Phase 2 ASSURE trial

Lantheus Medical Imaging supports FDA action to ensure appropriate use of gadolinium-based contrast agents

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

Varian to highlight new TrueBeam medical linear accelerator at ESTRO 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Legal and moral reasons prevent most Oregon hospices from participation in 'Death with Dignity Act'

Ortho Biotech unblinded abiraterone acetate Phase 3 study for prostate cancer patients

Current treatment strategies for mood and addictive disorders

Nucletron to present innovative cancer treatment during ESTRO29

Cancer Research UK launches world's first urban running lane on London's Southbank

Scottish government proposes minimum price to tackle alcohol misuse

'Seeking mental health treatment' is not a criteria for revocation of security clearance

Using opioids at end-of-life care proves effective to control pain

FASD ONE releases three research papers on Fetal Alcohol Spectrum Disorder

Mexican-American stroke survivors with atrial fibrillation at increased risk for second stroke

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News